California Public Employees Retirement System continued to hold its stake in shares of Acceleron Pharma Inc. (NASDAQ:XLRN) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 20,900 shares of the biopharmaceutical company’s stock at the end of the second quarter. California Public Employees Retirement System owned 0.05% of Acceleron Pharma worth $635,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Swiss National Bank lifted its stake in Acceleron Pharma by 8.4% during the second quarter. Swiss National Bank now owns 50,300 shares of the biopharmaceutical company’s stock worth $1,529,000 after purchasing an additional 3,900 shares during the last quarter. Birchview Capital LP bought a new position in Acceleron Pharma during the second quarter worth $456,000. AXA bought a new position in Acceleron Pharma during the second quarter worth $9,833,000. Teachers Advisors LLC lifted its stake in Acceleron Pharma by 2.1% during the first quarter. Teachers Advisors LLC now owns 46,080 shares of the biopharmaceutical company’s stock worth $1,220,000 after purchasing an additional 942 shares during the last quarter. Finally, TD Asset Management Inc. lifted its stake in Acceleron Pharma by 0.8% during the second quarter. TD Asset Management Inc. now owns 78,800 shares of the biopharmaceutical company’s stock worth $2,395,000 after purchasing an additional 600 shares during the last quarter. Hedge funds and other institutional investors own 75.85% of the company’s stock.

Acceleron Pharma Inc. (XLRN) opened at $38.71 on Friday. Acceleron Pharma Inc. has a fifty-two week low of $23.07 and a fifty-two week high of $40.35.

Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.02. The company had revenue of $3.00 million for the quarter, compared to analyst estimates of $3.52 million. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same period last year, the company earned ($0.55) earnings per share. analysts expect that Acceleron Pharma Inc. will post -2.67 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.dailypolitical.com/2017/11/19/california-public-employees-retirement-system-has-635000-holdings-in-acceleron-pharma-inc-xlrn.html.

Several equities analysts recently issued reports on the company. Zacks Investment Research cut Acceleron Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. BidaskClub cut Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Acceleron Pharma in a research note on Tuesday, November 14th. HC Wainwright raised their price objective on Acceleron Pharma from $57.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, November 7th. Finally, Credit Suisse Group set a $35.00 target price on Acceleron Pharma and gave the stock a “buy” rating in a research report on Saturday, August 5th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Acceleron Pharma presently has a consensus rating of “Buy” and a consensus price target of $44.88.

In other news, CFO Kevin F. Mclaughlin sold 16,000 shares of the firm’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $38.41, for a total transaction of $614,560.00. Following the transaction, the chief financial officer now directly owns 50,810 shares of the company’s stock, valued at $1,951,612.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Corp /De/ Celgene purchased 745,592 shares of the stock in a transaction dated Monday, September 25th. The shares were acquired at an average cost of $37.00 per share, for a total transaction of $27,586,904.00. Following the completion of the acquisition, the insider now directly owns 6,118,479 shares of the company’s stock, valued at approximately $226,383,723. The disclosure for this purchase can be found here. Insiders have sold 53,513 shares of company stock worth $2,055,485 over the last three months. Corporate insiders own 3.90% of the company’s stock.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Want to see what other hedge funds are holding XLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acceleron Pharma Inc. (NASDAQ:XLRN).

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.